{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:04:13Z","timestamp":1790111053372,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:14:03Z","timestamp":1782645243000},"page":"771-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Amanda J.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafinaz","family":"Eisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne C.W.","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"DePas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunan","family":"Selvarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellissa","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie J.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.06.012_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.06.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00185-2021","article-title":"Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration","volume":"59","author":"Morrison","year":"2022","journal-title":"Eur Respir J."},{"key":"10.1016\/j.jcf.2026.06.012_bib0003","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S2213-2600(24)00259-5","article-title":"Reflections 5 years on from the approval of ETI therapy","volume":"12","author":"Middleton","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.06.012_bib0004","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.jcf.2026.06.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest."},{"key":"10.1016\/j.jcf.2026.06.012_bib0006","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ppul.21011","article-title":"Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients","volume":"44","author":"Bjarnsholt","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.06.012_bib0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1569-1993(02)00104-2","article-title":"Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies","volume":"1","author":"Hoiby","year":"2002","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.012_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108782","article-title":"Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies","volume":"34","author":"Jennings","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2026.06.012_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.969326","article-title":"Biofilm aggregates and the host airway-microbial interface","volume":"12","author":"Hall-Stoodley","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jcf.2026.06.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027943","article-title":"Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm","volume":"6","author":"Alhede","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2026.06.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02696-16","article-title":"Importance of the exopolysaccharide matrix in antimicrobial tolerance of Pseudomonas aeruginosa aggregates","volume":"61","author":"Goltermann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2026.06.012_bib0012","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.201312-2142OC","article-title":"Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection","volume":"189","author":"Staudinger","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.06.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.116016","article-title":"The effect of Staphylococcus aureus on the persistence of Pseudomonas aeruginosa due to aggregation in cystic fibrosis airway infections","volume":"29","author":"Morris","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.jcf.2026.06.012_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.jcf.2026.06.012_bib0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1513\/AnnalsATS.201811-774OC","article-title":"Oral azithromycin and response to pulmonary exacerbations treated with intravenous tobramycin in children with cystic fibrosis","volume":"16","author":"Klingel","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.06.012_bib0016","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jcf.2015.07.010","article-title":"Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations","volume":"14","author":"Waters","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.012_bib0017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/thoraxjnl-2016-208450","article-title":"Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis","volume":"72","author":"Stanojevic","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.06.012_bib0018","series-title":"TRIKAFTA product monograph","author":"Pharamceuticals","year":"2024"},{"key":"10.1016\/j.jcf.2026.06.012_bib0019","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2014.09.013","article-title":"Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients","volume":"14","author":"Yau","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00796-16","article-title":"Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling","volume":"7","author":"DePas","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.jcf.2026.06.012_bib0021","doi-asserted-by":"crossref","DOI":"10.3791\/61631","article-title":"Visualization of Pseudomonas aeruginosa within the sputum of Cystic fibrosis patients","author":"Jackson","year":"2020","journal-title":"J Visual Exp: JoVE"},{"key":"10.1016\/j.jcf.2026.06.012_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25889-6","article-title":"Pseudomonas aeruginosa aggregation and Psl expression in sputum is associated with antibiotic eradication failure in children with cystic fibrosis","volume":"12","author":"Morris","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.06.012_bib0023","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/JCM.38.2.818-825.2000","article-title":"Specific and rapid detection by fluorescent in situ hybridization of bacteria in clinical samples obtained from cystic fibrosis patients","volume":"38","author":"Hogardt","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcf.2026.06.012_bib0024","doi-asserted-by":"crossref","DOI":"10.3791\/61759","article-title":"Quantifying the effects of antimicrobials on In vitro biofilm architecture using COMSTAT software","author":"Morris","year":"2020","journal-title":"JoVE"},{"key":"10.1016\/j.jcf.2026.06.012_bib0025","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.012_bib0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1574-695X.2010.00706.x","article-title":"The immune system vs. Pseudomonas aeruginosa biofilms","volume":"59","author":"Jensen","year":"2010","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.jcf.2026.06.012_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03148-21","article-title":"Combining Ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.jcf.2026.06.012_bib0028","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","article-title":"Impact of CFTR modulation on Pseudomonas aeruginosa infection in people with cystic fibrosis","volume":"230","author":"Ledger","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcf.2026.06.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2025.07.009","article-title":"Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation","volume":"33","author":"Durfey","year":"2025","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jcf.2026.06.012_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/jleuko\/qiad139","article-title":"Aberrant immune programming in neutrophils in cystic fibrosis","volume":"115","author":"Hu","year":"2024","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcf.2026.06.012_bib0031","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcf.2026.06.012_bib0032","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1702798114","article-title":"Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity","volume":"114","author":"Snarr","year":"2017","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:06:06Z","timestamp":1790107566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016541"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}